3,005 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Mendel Money Management

Mendel Money Management acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,005 shares of the life sciences company’s stock, valued at approximately $402,000.

A number of other hedge funds also recently bought and sold shares of ILMN. WCM Investment Management LLC grew its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares during the last quarter. ARK Investment Management LLC purchased a new position in Illumina in the fourth quarter worth $91,714,000. Janus Henderson Group PLC lifted its position in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares during the period. Nikko Asset Management Americas Inc. acquired a new stake in Illumina in the 4th quarter valued at about $65,813,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock worth $115,663,000 after buying an additional 466,519 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ILMN shares. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. Finally, Barclays reaffirmed an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Price Performance

Shares of Illumina stock opened at $87.53 on Wednesday. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $106.10 and its 200-day moving average price is $127.71. The firm has a market capitalization of $13.86 billion, a PE ratio of -11.40, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.